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CHAPTER I 
DETECTING AND PREVENTING ANTIBIOTIC RESISTANCE IN BACTERIA 
Introduction and Study Overview  
This Masters Thesis project had as its objectives: (1) to provide Vanderbilt 
University Hospital (VUH) with computerized tools for monitoring microbiological data; 
(2) to provide the VUH Infection Control Service with tools to help monitor and track 
infection-relevant patient-related data such as culture results, hospital location, current 
orders, and contact precautions status; and, (3) to initiate studies to improve compliance 
with VUH contact precautions policies – specifically, those for antibiotic-resistant 
organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant Enterococcus (VRE). Prior to this study, VUH microbiology data were only 
available in plain text format from the microbiology laboratory system as individual 
culture or study results. Clinicians viewed microbiology study results in a single patient-
specific manner through integration of the microbiology-result-containing laboratory 
system (GE’s “Triple G”® system) with VUH’s electronic medical record system 
(“StarPanel”). Access was limited to the text of the microbiology report only. For these 
reasons, antibiograms had to be constructed at VUH manually. Though this was done 
every six months for many years, time constraints ultimately forced bi-annual creation 
and distribution of antibiograms to be discontinued in 2005. As described in the 
remainder of this document, the project achieved success by creating and evaluating 
MicroTools, a suite of programs that address VUH’s infection control needs. 
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Bacterial Sensitivity to Antibiotics 
Antibiotic resistance in bacteria presents a growing problem to hospitals [1-9]. 
Antibiotic-resistant organisms such as MRSA and VRE cause infections that are more 
difficult or expensive to treat than their antibiotic-sensitive counterparts. Infections by 
resistant organisms often lead to more dire patient outcomes [7, 10-13]. 
The most common measurement used to determine the degree of antibiotic 
resistance present in a bacterial specimen is minimum inhibitory concentration (MIC) 
[14]. An MIC represents the lowest concentration of an antibiotic that is still able to 
prevent a microbe from growing during incubation on appropriate medium (such as an 
agar plate or agar broth containing specific nutrients) and is the current gold standard for 
determining susceptibility to antimicrobial agents [14]. Methods for calculating MICs 
include disk diffusion [15, 16], broth microdilution [17], agar dilution [17, 18], and the E 
Test (a newer method that tests many antibiotic concentrations simultaneously) [19]. 
Comparing MIC values for an organism/antibiotic pair with published breakpoints yields 
a determination of whether the organism is sensitive, intermediate, or resistant to the 
antibiotic [20, 21]. These breakpoints depend on pharmacokinetic and pharmacodynamic 
properties of the antibiotic, since to be effective and safe, the dosage given to a patient 
must effectively treat the infection without reaching a potentially toxic concentration in 
the body [22, 23]. When the MIC for an organism/antibiotic pair exceeds the level at 
which the body can safely tolerate the antibiotic (e.g., without substantial risk of 
ototoxicity or nephrotoxicity), the antibiotic cannot be used to safely treat the infection. 
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The Problem of Antibiotic-Resistant Bacterial Infections 
A major problem occurs when an organism develops resistance to the most 
common current method of treatment (e.g., oxacillin/methicillin for S. aureus). Repeated 
use of an antibiotic to treat an infection exerts a selective pressure on an organism that is 
an important determinant in the emergence of new antibiotic resistance. [5, 24, 25]  
Development of new antibiotics plays a small role in preventing resistance 
problems, since over-reliance on new antibiotics can lead to new resistance patterns. For 
example, linezolid, the first drug in a novel class of antibiotics, was approved for use in 
the United States in April of 2000 [26], but initial reports of resistance to linezolid 
appeared just one year later for both VRE [27] and S. aureus [28]. In addition, inter-
species transfer of resistance by bacterial plasmids occurs commonly [29-32]. The 
plasmid transfer mechanism allows antibiotic resistance genes to be passed from adaptive 
but relatively benign bacteria to a more virulent species that may cause serious infections 
in patients. Ultimately, to control and prevent the spread of antibiotic resistance, hospitals 
must make a coordinated effort to both curtail the spread of currently antibiotic resistant 
organisms and prevent the emergence of new antibiotic resistant organisms [33].  
Preventing the Emergence of New Antibiotic-Resistant Organisms 
Attempts to inhibit or reverse antibiotic resistance in hospitals vary in their 
approach. The most basic method simply restricts the use of clinically important “potent” 
(and often expensive) antibiotics -- e.g., vancomycin or linezolid -- to cases where their 
use is strictly necessary on the basis of severity of infection, knowledge of the most likely 
causative organisms to treat before culture results are known, and actual patterns of 
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antibiotic sensitivity once culture results become available [33]. Careful use of antibiotics 
can lead to both decreased antibiotic costs and improvements in antibiotic susceptibility 
rates [34-37]. However, it should be stressed that limiting antibiotic use must be a 
coordinated effort hospital-wide; only limiting antibiotic use in single wards may not 
significantly reduce the incidence of antibiotic resistance for an institution [38]. 
Furthermore, antibiotics not covered by a hospital-wide antibiotic restriction policy tend 
to be misused more frequently, suggesting a real need for guidance from hospital 
administration [39]. 
The efficacy of antibiotic restriction is necessarily limited, however, as a given 
antibiotic must be available for the antibiotic to be useful. For this reason, several 
methods of restricting antibiotic use without outright discontinuation of their use have 
been proposed. One method involves limiting the antibiotics prescribed within the 
hospital via two common techniques. The first, antibiotic cycling, involves rotating the 
antibiotics used within the hospital [40]. In the second technique, combination antibiotic 
therapy, clinicians prescribe multiple antibiotics that can adequately treat an infection 
[41-43]. Thus, if a mutation yielding antibiotic resistance occurs in an organism, one of 
the other active antibiotics will prevent it from propagating. In general, antibiotic cycling 
is less efficient than combination antibiotic therapy at preventing antibiotic resistance 
[44, 45]. Furthermore, combination antibiotic therapy can reduce mortality rates in 
severely ill patients, thus providing additional therapeutic benefits that antibiotic cycling 
cannot [43, 46].  
Newer techniques to improve antibiotic use involving computer-assisted antibiotic 
selection have shown promise [47-49]. Due to the extensive knowledge requirements 
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associated with antibiotic selection, taking all relevant factors into account is impossible 
without consulting outside sources [50]. The earliest developed antibiotic selection 
program was Shortliffe’s pioneering MYCIN, a program that performed as well as or 
better than human physicians [51, 52] on paper-based evaluations, but which was never 
implemented in full-scale clinical practice. Later automated antibiotic selection efforts at 
LDS Hospital [53-55] and West Virginia [56, 57] achieved acceptable clinical 
performance in actual hospital settings. 
Combining antibiotic restriction with combination therapy provides a currently 
effective means of slowing the development of new resistant organisms, and effectively 
incorporating computer assistance gives future opportunities for improvement. However, 
it is unlikely that even the strictest adherence to antibiotic restriction and combination 
therapy could completely prevent resistance from developing. Community-acquired 
antibiotic-resistant organisms provide an additional reservoir that lies beyond the reach of 
any single hospital’s antibiotic stewardship program, and resistant organisms are already 
endemic in many areas. For these reasons, hospitals must also implement a plan to stop 
resistant organisms from spreading. 
Preventing the Spread of Resistant Organisms 
Basic infection control measures such as hand washing [58, 59] and staff 
cohorting (i.e., dedicating one group of nurses to working with all patients with a certain 
type of infection) [60-63] can help prevent MRSA, VRE, and other antibiotic-resistant 
organisms from spreading [64-66]. However, standard precautions are not always 
sufficient to avoid crossinfection [67]. For this reason, many hospitals dictate the use of 
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contact precautions for patients with antibiotic-resistant infections. Contact precautions 
give hospitals a relatively inexpensive and effective approach to avoid the spread of 
antibiotic-resistant organisms. Contact precautions aim to directly prevent the spread of 
resistant organisms by effectively isolating patients infected with resistant organisms [7, 
68-70].  
When starting contact precautions, the nursing staff first moves the infected 
patient into a private room. For infections spread by contact with infected or colonized 
patients and their environment (e.g., MRSA or VRE), all healthcare providers must wear 
gloves and gowns before entering the room and remove them as they exit [68-70]. Once 
the infection (or bacterial colonization) has been cleared, those who enter the patient’s 
room no longer need to follow contact precautions. 
If strictly implemented, contact precautions effectively prevent antibiotic-resistant 
infections from spreading and can help contain outbreaks as well [71-78]. Unfortunately, 
studies have also demonstrated that contact precautions may adversely affect the safety 
and outcomes of patients on contact precautions due to decreased patient observation 
time and lesser interaction with professional staff. These result from the increased 
demands (donning and removing protective attire) on providers caused by contact 
precautions protocols [79]. Nevertheless, contact precautions remain a key measure in 
infection control thanks to the patient safety benefits from reduced transmission of 
resistant organisms. 
Non-compliance by caregivers limits the effectiveness of contact precautions. 
Hospital-based infection control practitioners often battle non-compliance even with 
relatively simple infection control interventions like proper hand hygiene [80, 81]. Thus, 
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it is not surprising that studies have demonstrated compliance problems with contact 
precautions. In one study conducted at the University of Iowa, hospital staff correctly 
followed the hospital-defined contact precautions protocols when dealing with patients 
only 41% of the time [82, 83]. Given the efficacy of contact precautions and the tendency 
of hospital staff to stray from them, hospitals should pursue methods capable of 
improving adherence to contact precautions policies. 
Addressing Information Needs in Infection Control and on the Wards 
To determine the effectiveness of an intervention that attempts to improve contact 
precautions compliance rates for inpatients infected or colonized with resistant 
pathogens, one needs to be able to accurately identify when patients require contact 
precautions. However, monitoring and detecting cases of non-compliance with 
established contact precautions protocols can be difficult. Typically, most hospitals, even 
in the present information age, carry out compliance monitoring tasks by manual direct 
inspection of patient charts, of patients, and of patient isolation rooms. Data collected 
manually may be stored on paper forms, in electronic spreadsheets, or in localized PC-
based databases. Infection control practitioners must consult many different information 
resources to detect non-compliance. They require current hospital census information to 
know who is currently admitted to or being evaluated in the hospital; microbiology 
culture data to determine which patients have drug-resistant infections or colonization; 
and information about which patients are currently isolated. Gathering such 
comprehensive data is daunting and time-consuming, particularly in hospitals lacking a 
good information technology infrastructure.  
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In clinical settings where existing electronic medical record systems (EMRs), 
admit-discharge-transfer (ADT) systems, laboratory information systems, and care 
provider order entry (CPOE) systems are in use, electronic dashboards can provide a 
potentially useful method for reducing the burden of data gathering [84-86]. Dashboards 
collect and summarize a large amount of information from different sources and display 
integrated and synthesized information for quick consumption. With the growth of 
information technology in medicine, dashboards are now available more frequently in the 
hospital setting [84, 86, 87]. 
Computerized reminders can help to improve compliance with hospital policies 
[88-93]. In a study at Indiana University Medical Center, Dexter et al. observed a large 
increase in physician ordering of preventive therapy measures after implementing 
computerized reminders [88]. Individual physicians’ behaviors varied widely, however, 
with some following the recommended orders more than 80% of the time and others 
disregarding all or nearly all recommendations [89]. Litzelman et al. conducted a study 
measuring the effects of computerized reminders on physicians’ ordering rates of 
preventive care measures at Regenstrief Health Center [90]. They found that the 
computerized reminders improved residents’ ordering rates by 20-35%, though attending 
physicians’ ordering rates did not change significantly. Neilson et al. also found that peer 
management in the form of computerized reminders reduced physician ordering rates of 
unnecessary tests, further suggesting that computerized reminders can be effective in 
changing physician behavior [91]. 
Kho et al. found that computerized reminders could help improve compliance 
with contact precautions policies at Indiana University Medical Center [92, 93]. After 
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identifying incoming inpatients who had past-documented MRSA or VRE cultures, Kho 
et al. generated a computerized alert reminding physicians to write a contact precautions 
order for those inpatients. Within that identified population, compliance with contact 
precaution policies rose from 33% to 89%. 
Overall, the evidence suggests that providing useful information to clinicians at 
the proper time can often help improve their compliance with hospital policy. Thus, 
providing information on which patients require contact precautions when a clinician 
places orders could have a positive impact on overall contact precautions rates. 
Detecting and Monitoring Antibiotic Resistance 
A standard tool for monitoring antibiotic resistance patterns in hospitals is the 
antibiogram [94]. Antibiograms aggregate observed antibiotic sensitivities over a period 
of time for various organisms. Thus, they provide a basis for empiric therapy when new 
infections are identified. Currently, most antibiograms are created manually, including at 
VUH. Unfortunately, the data represented in manually created antibiograms are often 
immediately out of date, giving clinicians a less accurate indication of which antibiotics 
to use. Since antibiograms require a large amount of accurate, up-to-date information, 
computers systems to aid in their creation provide an immediate benefit for improved 
patient care [53, 57, 94-97]. Furthermore, eliminating the tedious and time-consuming 
task of collecting and organizing antibiotic resistance data allows infection control staff 
to spend their time more productively. 
Among the earliest efforts at automating antibiotic resistance monitoring is the 
Computerized Infectious Disease Monitor (CIDM) created at LDS Hospital by Evans et 
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al. [96]. The CIDM was incorporated into LDS Hospital’s larger HELP hospital IT 
system to integrate information from their microbiology laboratory system. The CIDM 
ran daily in the afternoon and generated a variety of alerts for infection control staff when 
it detected situations requiring attention. Overall, the CIDM performed quite well, 
detecting infections as accurately as infection control staff and making accurate and 
clinically useful antibiotic suggestions [97]. At Barnes Hospital in St. Louis, Kahn et al. 
developed GERMWATCHER, a computerized expert system used to detect nosocomial 
infections [95]. Though not technically used for tracking antibiotic resistance, the model 
they developed provided enough flexibility to do so. The microbiology laboratory system 
at Barnes Hospital generated microbiology reports in a semi-structured form, using 
natural-sounding language but backed by a limited terms dictionary. Leveraging the 
terms dictionary, they were able to use simple pattern matching to extract the portions of 
the report necessary for tracking nosocomial infections. Wright et al. developed a system 
that allowed infection control staff to set “control charts” that would generate an alert 
when certain organisms were detected [98]. The control charts allowed alerts to be 
displayed any time the organism was detected, only if it had certain antibiotic resistances, 
or only if it was in a certain unit. After configuring the control charts and analyzing 
retrospective data, the program was able to detect a number of outbreaks that infection 
control had missed, making this a potentially useful tool for surveillance. Brossette et al. 
developed a similar system but took a slightly different approach. Their program was 
designed to detect changes in resistance patterns as well, but the program ran 
independently; it was not informed of any preconceptions about what would constitute a 
clinically interesting pattern rather than an obvious pattern [99]. By observing differently 
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sized blocks of time, Brossette et al. were able to detect a number of interesting short-
term and long-term changes in the resistance patterns shown by Pseudomonas 
aeruginosa.  
Regardless of the methodology employed, hospitals must use resistance data 
when determining hospital antibiotic use policy and when making frontline antibiotic 
decisions. Without this information, clinicians can easily make mistakes that can result in 
an improperly treated infection or in the fostering of new antibiotic resistance. 
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CHAPTER II 
DEVELOPMENT AND VALIDATION OF MICROPARSE 
Introduction: Development and Validation of MicroParse 
Providing VUH with automated tools for monitoring microbiological data first 
requires an accurate source of microbiological data. VUH uses a proprietary 
microbiology lab system (Triple G®) that does not allow access to its underlying 
database, thus making direct access to the microbiology data impossible. The plain text 
reports supplied by the microbiology lab system to physicians provide the only easily 
accessible method of output. For computerized tools to make use of the plain text reports, 
however, another tool must first parse the reports into a coded format. The MicroParse 
project aimed to provide the parsing functionality. 
Methods: Development and Validation of MicroParse 
Clinical Setting and Microbiology Data Source 
Vanderbilt University Hospital is an 832-bed academic medical facility located in 
Nashville, TN. Its microbiology lab system, GE Medical Systems’ Triple G®, processes 
over 20,000 unique microbiology culture and test reports per month. Unfortunately, the 
proprietary software underlying Triple G® generates microbiology reports in a human-
readable format with variable structure that makes report parsing (by computer 
algorithms) to identify pathogen names and other characteristics less than straightforward 
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(Figure 1). Thus, to use VUH microbiology report data for decision support requires 
sophisticated parsing algorithms that “understand” the component parts of reports and 
that can recognize the underlying lexicons from which reports are generated. 
 
 
 
Figure 1: Sample plain text report from Triple G® 
Description of MicroParse 
The project (authors RC and RM) created a parser (MicroParse), written 
originally in Perl and later in PHP, to process the Triple G-generated microbiology text 
reports into usable microorganism-related data. At present, for purposes of security, 
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confidentiality, and convenience of data access, MicroParse runs on machines within the 
StarPanel cluster; StarPanel is VUH’s electronic patient record. StarPanel was configured 
to regularly feed plain text Triple G® microbiology reports to MicroParse, which 
processes new reports every 10 minutes that are in turn passed back to StarPanel for 
storage.  
MicroParse first decomposes each plain text Triple G® report into 4 potential 
sections (when present): preamble, Gram stain, culture, and susceptibilities (Figure 1). 
The preamble contains information about the culture result, including the culture category 
(e.g., blood, CSF, urine), the report time and date, the report status (i.e., preliminary or 
final), and the site from which the specimen was taken (e.g., arm wound, bone marrow). 
Because the preamble tends to follow a fairly specific order with common terms, this 
information is easily recognized using Perl-style regular expressions. For example, to 
extract the report’s status, MicroParse uses:  
/Report status:([a-zA-Z ]+)/ 
 
The Gram stain and culture sections are more difficult to parse since they more 
closely approximate natural language. However, text from these sections comes primarily 
from the dictionary of microbiology terms (“VUH Microbiology Thesaurus”) stored 
within Triple G®. To generate reports, lab technicians simply select finding codes based 
on the results of the test or culture; Triple G® then enters a standardized phrase into the 
report, but combined in a manner with surrounding and intermingled English text phrases 
that make recognition of the original coded terms difficult. Fortunately, unlike most other 
data within the Triple G® database, the microbiology terms dictionary is externally 
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accessible. This allows MicroParse to use an externalized copy of the VUH Microbiology 
Thesaurus as an aid to parsing reports.  
The susceptibilities section of VUH Microbiology reports contains a table that, in 
its top row, indicates an abbreviation for each isolated bacterium, and on subsequent 
rows, indicated only by column position, the results of testing each organism’s growth in 
the presence of various antibiotics. The antibiotics for which susceptibilities were tested 
are named in the first (leftmost) column of the table rows (except the first row). The table 
columns are generally fixed-width fields, though complications can arise. For example, 
the abbreviated names often run together in the first row and the abbreviations are 
occasionally inconsistent (e.g., nonspecific coagulase-negative staphylococcus can appear 
with any of 6 different column headings). Without consistency in the column names, 
demarcating the column breaks can be difficult. Also, when the microbiology laboratory 
provides minimum inhibitory concentrations for a given isolated bacterium, unpredictable 
changes occur in the column alignments. When multiple bacteria grow from a single 
culture and their sensitivities are presented as side-by-side columns in a report, it is often 
the case that not all organisms were tested against all antibiotics, so the absence of testing 
is indicated by blank fields (extra spaces) within the table columns – further complicating 
the parsing task. 
After processing the report, MicroParse stores the information in a MySQL 
database, also located within the StarPanel machine cluster. Figure 2 shows an example 
of the parsed fields for one of the lines in the report shown in Figure 1. In this case, 
MicroParse stores the codes IITO (“isolated in thio only”) and STRALP (“streptococcus 
alpha”), and labels their identification status as “final.” The database then interfaces with 
 16 
 
StarPanel to provide information about organisms identified in the report to other 
programs. 
Parsing the Gram Stain and Culture Sections 
Much of the text found in both the culture and Gram stain sections is drawn 
directly from the VUH Microbiology Thesaurus. For example, to identify an isolated 
bacterium in the culture section, it is common to see a term from the categories QUANT 
(quantity) and FIDORG (final identified organism) (Figure 2).  
 
 
Figure 2: Breaking culture/gram stain sections into component terms 
The Thesaurus helps MicroParse to process the Gram stain and culture results. 
The Gram stain segment of the report tends to be straightforward, as nearly all lines 
consist of a STAINQTY term followed a STAINDESC term, making the parsing process 
simple. The culture section often contains more complex information, however. 
To parse the culture section, MicroParse first processes the VUH Microbiology 
Thesaurus into a compiled format nicknamed “the Microbiology Rosetta Stone.” To 
create the Microbiology Rosetta Stone, MicroParse breaks each phrase in the terms 
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dictionary into its constituent words. Starting with the first word in the phrase, 
MicroParse then creates a linked list from these words, thus storing the valid partial 
phrases along with an indication of where completed phrases end (Figure 3). 
 
 
Figure 3: Creating the Microbiology Rosetta Stone 
Once MicroParse has created the Microbiology Rosetta Stone as a reference 
source, it is ready to process the text in the culture section. Starting with the beginning of 
a microbiology report’s culture segment, MicroParse matches one word at a time against 
the list of valid partial phrases until adding the next word from the report text would 
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create a phrase that does not exist in the terms dictionary. At that point, MicroParse takes 
the longest complete phrase it found and begins searching for the next phrase starting 
with the end of the previous one (see Figure 4). A placeholder entry in the Microbiology 
Rosetta Stone, UNPARSED, captures all phrases MicroParse encounters that do not have 
any valid matches in the dictionary.  
 
Figure 4: Parsing Text Using the Microbiology Rosetta Stone 
 
Database Structure 
The database centers around the specimen table. Each report issued by the 
microbiology laboratory system corresponds with one entry in specimen, and all 
general information about the report (e.g., time and date the specimen was received, time 
and date of the report, site the specimen was drawn from) is stored there along with a 
unique ID number, specimen_id. 
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The specimen_id directly links specimen to the gramstain table, which 
contains a quantity and finding for each entry listed in the Gram stain section of the 
report. The specimen_id also links specimen to the specimen_result table. 
Each result from the culture section of the report has one entry in specimen_result, 
with each parsed phrase from specimen_result stored in 
specimen_result_rosetta. Finally, specimen_id links specimen with the 
sensitivity. In sensitivity, each organism with antibiotic sensitivities given in 
the report has one entry, with individual results for each antibiotic/organism pair stored in 
abxsuscept. In this fashion, all portions of the standard report link together through 
specimen. Figure 5 graphically illustrates this linkage. 
 
 
Figure 5: Relational Database Core Structure 
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The database structure works well with MicroParse, with each of the four report 
sections having a direct mapping to a table or set of tables within the database. Thus, after 
MicroParse processes the report, storing the information becomes a straightforward 
process.  
Validation of MicroParse Data Capture 
To confirm that MicroParse can properly parse reports and retrieve the clinically 
relevant information from them, we conducted a validation study. We first selected 3 
dates that fell on different days of the week to analyze: Saturday, January 6, 2007, 
Monday, January 15, 2007, and Friday, January 19, 2007. We then acquired a complete 
data dump of all reports issued on those three days from the microbiology laboratory 
system. 
Taking this information, a computer program matched the reports to records in the 
MicroParse database. We collected all of the matched reports and displayed them on a 
webpage containing 4 panes: the upper left displayed the report text MicroParse received 
and parsed, the upper right displayed the parsed output stored in the MicroParse database, 
the lower left displayed the data from the microbiology lab system, and the lower right 
contained controls allowing the reviewer to input comments on the displayed report and 
to navigate to the other reports to review. Figure 6 shows a screenshot from the validation 
webpage. 
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Figure 6: Webpage designed for the MicroParse validation 
 
We chose our most clinically experienced collaborator, Dr. Thomas Talbot, to 
conduct the actual validation. Dr. Talbot reviewed all of the matched records from the 
above-mentioned sample to confirm that the information stored in the MicroParse 
database accurately reflected all relevant content found in the original microbiology lab 
report.  
Results: Development and Validation of MicroParse 
MicroParse Results 
MicroParse currently handles approximately 500-900 VUH microbiology reports 
per day. It is able to process and store reports at a peak rate of approximately 15 reports 
per second, yielding a theoretical limit of over 1,000,000 reports per day. MicroParse 
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identifies a phrase in the Microbiology Rosetta Stone for over 98% of the text contained 
in the culture section and nearly 100% of the text in the Gram stain section. 
Figure 7 shows the number of unique MRNs with an MRSA-positive inpatient 
culture result by month. As the trend line shows, the rate of MRSA at VUH 
approximately doubled between January 2001 and January 2006. 
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Figure 7: Unique MRNs with MRSA-positive inpatient culture by month 
MicroParse Validation Study Results 
Figure 8 shows the results of the MicroParse validation study. Out of the 1,895 
reports reviewed, 28 had expert reviewer-generated comments (1.5%). Of the commented 
reports, 17 were problems in MicroParse, 2 were problems where a preliminary report 
was matched to a final report, 1 was a Triple G®-related problem, and 8 were general 
comments and questions. Overall, the validation process demonstrated that the core 
functionality of MicroParse was working as expected, with problems occurring in three 
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main areas: Microbiology Thesaurus term labeling, positive/negative culture tagging, and 
report linking. 
 
 
Figure 8: Validation results 
Out of 1895 reviewed reports, 28 had comments. 17 comments related to problems within MicroParse, 2 
were problems in the report creating the validation set, 1 was a Triple G® problem, and 8 were questions 
and comments that did not indicate problems. Of the 17 MicroParse problems, 4 were Microbiology 
Thesaurus term issues, 11 were problems with the positive/negative tagging system, and 2 were problems 
with linking related reports. 
 
The MicroParse Microbiology Thesaurus term labeling problems primarily 
involved the redisplay of parsed information. Since the creation of the Microparse 
version of Microbiology Thesaurus terminology involves stripping most punctuation 
from the “raw” feeds from Triple G® to create canonical terms, displaying the 
descriptions associated with the resulting codes stored by MicroParse can be somewhat 
misleading. For example, the QUANT code 1025k is associated with the text “10-25k”, 
but the Microbiology Thesaurus entry for it appears as “10 25k” without the dash. 
Because the MicroParse version of the Microbiology Thesaurus originally only stored the 
canonical, “stripped down” version of the text in the database at the time of the validation 
study, that information was the only piece the reviewer was shown. Thus, the reviewer 
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was concerned that the code might not correctly represent the report. These problems 
were easily solved by adding the original text into the Microbiology Thesaurus as an 
extra field to be shown when redisplaying the parsed report results. 
The positive/negative tagging problems centered on the system devised for 
MicroParse to identify positive cultures. Some of the Microbiology Thesaurus term 
entries are somewhat ambiguous as to whether or not they represent a positive, negative, 
or indeterminate culture. For example, one could argue that “no growth; reincubate” 
could be counted as a negative result or as an indeterminate result. As the most 
commonly occurring problem discovered in the validation, we are currently working on a 
new, more flexible tagging system that should alleviate some of the encountered 
problems. 
The report linking problems identified in the MicroParse validation study arose 
when there were free text entries in the report telling the user to refer to another report for 
more detailed information about the current report (often sensitivity information). As free 
text, the instruction is worded differently in different reports, and the methods used to 
reference other reports vary as well. However, in many of the observed cases, the 
references cited a portion of the accession numbers given to all reports from a given 
patient sample.  
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Summary and Conclusions: Development and Validation of MicroParse 
Principal Findings of MicroParse Validation 
As demonstrated by the validation study, MicroParse performed quite well. 
MicroParse processes and stores reports very quickly and should scale well even if the 
number of reports processed by VUH increases significantly. Most of the issues 
encountered by the reviewer took little effort to fix. The problem with linking reports 
based on free text references within one of the reports presents a more difficult obstacle, 
but more sophisticated parsing techniques could potentially extract the information 
contained in the references. 
Study Limitations during MicroParse Validation 
The phrase-matching algorithms employed by MicroParse are quite simple and 
can be prone to error. When MicroParse encounters free text in a report, it will still 
attempt to match the text to phrases in the Microbiology Rosetta Stone and could 
potentially find spurious matches. For example, if the text “not consistent with 
Pseudomonas aeruginosa” appeared in a report, MicroParse would lump “not consistent 
with” into an UNPARSED phrase, but would match “Pseudomonas aeruginosa” to the 
encoded phrase PSAER, incorrectly suggesting that P. aeruginosa was present in the 
culture. Furthermore, important information such as the report linkage free text cannot be 
retrieved simply by using the phrase matching. 
Nonetheless, the phrase matching technique provides several advantages as well. 
Since the vast majority of the text is made up of Microbiology Rosetta Stone phrases, 
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MicroParse correctly interprets a great deal of the report without any of the potential 
ambiguity that a more powerful natural language processing (NLP) technique might 
produce. In addition, implementing NLP techniques to parse UNPARSED phrases could 
allow MicroParse to take advantage of the benefits of both phrase matching and more 
advanced techniques. 
The database structure is well-suited for interoperating with MicroParse, but from 
a database design standpoint, the structure is not optimal. In particular, the database has 
not been fully normalized. Database normalization involves moving redundant 
information within one table to a new table [100]. In general, database designers should 
strive for highly normalized tables, as normalization reduces data redundancy and 
prevents data anomalies. 
In this database design, for example, an entry in the specimen table corresponds 
with a report received from the microbiology laboratory system. However, multiple 
entries in specimen are linked by specimen_accession, a value that uniquely 
identifies the sample from which the report was generated. Thus, when MicroParse 
processes multiple reports from a single specimen, it stores in the database redundant 
information such as medical record number (specimen_mrn), hospital unit 
(specimen_unit) and culture type/subtype (specimen_type and 
specimen_subtype), among others. To better normalize the database, we could thus 
add an accession table that stores an accession number with all shared information 
that links to several entries in specimen. 
However, database normalization carries several side effects. First, database 
normalization requires consistent information. For example, if it was discovered that a 
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patient had mistakenly been assigned a second medical record number and the error was 
fixed between a preliminary culture result and the final result for a specimen drawn from 
that patient, the normalized database design would either (1) have a second entry in 
accession for the new accession number/medical record number combination or (2) 
discard either the new or old medical record number. In the first case, we would lose the 
convenient mapping of one entry in accession to one patient sample, making working 
with the database more difficult. In the second, we would needlessly discard information. 
Under the current design, each the two entries in specimen would still share the same 
specimen_accession value but would have different specimen_mrn values. This 
inconsistency is not problematic for our purposes since we can still link the two results to 
the same patient sample, and we maintain the one specimen entry to one culture result 
model without discarding any information. 
In addition, since normalization creates more tables in a database, when retrieving 
information, the database package must perform more table joins, reducing reading 
performance. Since MicroParse only writes to the database once per report but other 
applications may perform many read attempts on each report, read access to the tables 
needs higher priority than write access. 
Significance of Results of MicroParse Validation Study 
MicroParse provides VUH with new opportunities. Studies and monitors 
involving microbiology data that would have previously involved chart reviews no longer 
require this potentially costly and time-consuming activity. Informatics staff have already 
begun a study on Group B streptococcal infections in pregnant women using the data 
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from MicroParse, and a monitor for Bordetella pertussis runs in association with an 
infection control study. MicroParse also provides the basis for the rest of this Master’s 
Thesis project. 
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CHAPTER III 
A RETROSPECTIVE ANALYSIS OF CONTACT PRECAUTIONS FOR VUH 
INPATIENTS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS 
(MRSA) AND VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) ISOLATES 
Introduction: Retrospective Analysis of Contact Precautions 
The long-term objective of this project is to design, build, implement, and 
determine the efficacy of an intervention that increases contact precautions ordering rates 
for inpatients with MRSA or VRE infections. Yet to accomplish this task requires 
baseline infection rate information. For this reason, we conducted a retrospective study to 
measure the overall compliance with VUH’s contact precautions policy for patients with 
MRSA and VRE isolates. As an adjunct to this retrospective study, and in preparation for 
the overall goal, the current project developed a dashboard to help VUH Infection 
Control staff to track information and notifications on patients with MRSA and VRE 
isolates and to allow project staff to collect retrospective and real-time information on 
contact precaution status and clinician isolation ordering rates. 
Background: Retrospective Analysis of Contact Precautions 
VUH Infection Control Service 
The VUH Department of Infection Control and Prevention manually conducts 
surveillance “walk rounds” to determine and verify the actual contact precautions status 
of patients, and to monitor their progress. Both MRSA and VRE infections are often 
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acquired within hospitals. Hospital policy at VUH (and many other institutions) requires 
contact precautions for patients who have recent culture isolates for these organisms. 
Thus, the VUH Infection Control team monitors for patients colonized or infected with 
these organisms with a two-step process. First, Infection Control Practitioners (ICPs) 
compile the list of all inpatients with newly identified isolates of MRSA, VRE, and other 
drug-resistant or CDC-reportable organisms. The ICPs compile the list based on 
information that the microbiology lab delivers manually via telephone calls. The data 
from phone calls is supplemented by review of individual patient records in StarPanel. 
Then, ICPs conduct work rounds by walking through the hospital to determine which 
patients should be, and currently are, on contact precautions. Combining the results of 
these surveys with the microbiology data allows ICPs to identify those patients who 
require isolation but who are not yet isolated. For appropriate patients, the Infection 
Control team then recommends initiation or discontinuation of contact precautions to the 
clinicians caring for those patients. 
Though the current Infection Control MRSA/VRE surveillance process works 
well, potential for improvement exists. Because the ICPs only can survey culture results 
and contact precautions status via rounding once per work day, day-long or weekend-
long time lapses can occur between the first identification of a drug-resistant organism 
and the ICP taking appropriate actions, such as recommending contact precautions when 
isolation has not been ordered. In many cases, microbiology laboratory technicians act as 
a safety net, and will inform the ICPs of any particularly unusual results with a phone 
call. Nevertheless, gaps in this manual system can still occur, which might potentially 
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result in the spread of MRSA or VRE from an infected patient if contact precautions are 
not followed. 
The project was able to externalize relevant data available from MicroParse to 
create a Web-based, real-time automated monitor to help ICPs follow inpatients with 
antibiotic-resistant bacterial isolates. The monitor concurrently tracks and displays this 
information for all relevant patients throughout VUH. This can potentially make 
identifying patients who require isolation a more straightforward process, providing the 
ICPs with access to the most up-to-date antibiotic resistant culture result information 
available. 
By monitoring active CPOE system orders on inpatients, it is possible to capture 
another relevant aspect of contact precaution information. Generally, based on evidence 
accumulated by ICPs on their rounds, if a physician issues an order for contact 
precautions for a patient, it is a safe assumption that hospital staff will properly follow the 
order and initiate contact precautions for the patient, making a manual check less 
important. Unfortunately, the converse cannot be automatically assumed. In other words, 
the lack of an order for contact precautions does not necessarily indicate that a patient 
was not placed on contact precautions. 
A patient on contact precautions may not have an active contact precautions order 
for several reasons. After learning of a patient with a new MRSA or VRE positive culture 
result, nursing unit personnel may act independently to initiate contact precautions per 
protocol (through hospital policy). Alternatively, an ICP may issue a recommendation to 
institute contact precautions for a patient without placing an order in the CPOE system. 
Similarly, if a physician gives a verbal contact precautions order, unless a staff member 
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remembers to enter the order into the CPOE system later, the contact precautions order 
may never be registered in the CPOE system, even though it is carried out. Another 
potentially problematic scenario might occur when a physician or nurse enters a CPOE 
order to initiate contact precautions, but does so as a free-text nursing order, rather than 
using the encoded order (e.g., “Nursing: please place this patient in a room with 
appropriate supplies and precautions to insure hospital protocol for MRSA infections is 
followed”). In such cases, the task of correctly identifying a patient’s contact precaution 
status becomes substantially more difficult to do algorithmically than simply searching 
for an encoded contact precautions order.  
For all of the above-listed reasons, the order data stored within the CPOE system 
may not necessarily represent a patient’s true contact precautions status. Thus, accurately 
determining the overall contact precaution status for all hospitalized patients requires 
some degree of manual confirmation. However, CPOE order data can provide a good 
“first pass,” yielding a starting point that will reduce the ICPs’ workload. 
Methods: Retrospective Analysis of Contact Precautions 
MRSA/VRE Infection Control Dashboard 
As described previously, the current method that the ICPs use to track patients’ 
contact precautions status starts by checking all hospital rooms. With the data available 
from MicroParse, however, the ICPs could instead start by checking patients with known 
antibiotic-resistant infections or colonization and would thus reduce their workload. The 
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MRSA/VRE Infection Control Dashboard (MicroDash) facilitates the process of finding 
patients with MRSA or VRE to allow them this opportunity. 
MicroDash consists of several functional units. The first is the data aggregator. 
The aggregator queries MicroParse for all culture results positive for MRSA or VRE and 
merges this information with current census data drawn from VUH’s ADT system to 
determine which patients with a current or past positive culture for MRSA or VRE are 
presently hospitalized. For each inpatient on the merged list, the aggregator draws 
information from VUH’s CPOE system to determine if they have an active contact 
precautions order. The results are cached on the StarPanel servers. 
The next functional unit, the dashboard webpage, displays the cached data. It sorts 
the list of inpatients by nursing unit. Information about the patient’s contact precautions 
status is displayed in 3 columns. The first is automatically populated and shows whether 
the aggregator identified a contact precautions order. The other two columns display 
whether the patient should be isolated and whether they are currently isolated; both fields 
are editable by the ICPs to reflect the results of their manual reviews. Figure 9 shows a 
screenshot from the dashboard webpage. 
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Figure 9: MRSA/VRE Infection Control Dashboard webpage 
Retrospective Study of Contact Precautions Implementation 
The study described in this section was reviewed by Vanderbilt University’s 
Institutional Review Board in March 2006 with approval number #060237. To establish a 
baseline rate at which VUH clinicians order contact precautions for patients with MRSA 
or VRE isolates, we reviewed all VUH adult inpatient microbiological cultures from 
January 2001 through January 2006.  
First, the “raw” Triple-G® microbiology reports in StarPanel were passed through 
MicroParse. Next, an automated program identified all inpatient and outpatient cultures 
which were positive for MRSA or VRE. Since patients could have multiple positive 
MRSA/VRE cultures during one hospitalization, we used a program that reviewed VUH 
CPOE log file data to compare the positive culture dates with hospital admission and 
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discharge dates, and determined the first positive MRSA/VRE isolation date for each 
patient admission in which a positive culture occurred. 
Next, for each of these hospital admissions where an MRSA or VRE positive 
culture occurred, an automated program retrieved all CPOE nursing orders from each 
relevant patient’s hospital stay. An automated program identified all contact precaution 
orders based on having unique orderable ID codes. The program further searched all free-
text nursing orders for words and phrases suggesting that a given order was a contact 
precautions order (e.g., containing “contact”, “precaution*”, or “isolat*”). Finally, an 
automated program calculated the time that elapsed for that patient during that admission 
from the time of the first positive MRSA/VRE culture until the time of issuing the first 
contact precautions order. Patients with contact precautions orders antedating the first 
positive culture isolate were excluded from this portion of the analysis and analyzed 
separately. We set a maximum possible contact precautions order delay of 14 days to 
prevent extreme outliers from skewing the aggregate results. An automated program also 
cataloged all instances when no isolation order was issued during the admission, before 
or after a positive culture isolate. 
Results: Retrospective Analysis of Contact Precautions 
During the 61-month study period, there were 384,957 inpatient culture results. 
Of these culture reports, 3,303 (0.86%) contained MRSA and 530 (0.14%) contained 
VRE. Eliminating multiple positive cultures during the same admission yielded 2,268 
MRSA/VRE cases. Matching these to contact precautions data from the VUH CPOE 
system yielded 1,019 patients properly placed on contact precautions before or after a 
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positive MRSA/VRE isolate, for an overall rate of 45.1%. This aggregate figure of 45.1% 
includes 132 patients placed on contact precautions prior to the culture result and 887 
patients with precautions following the culture. An average time of 3.6 days elapsed 
between the positive result and the contact precautions order for the 887 patients who had 
a contact precautions order after the result. Figure 10 shows the average time lapse 
between a positive culture and the contact precautions order. 
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Figure 10: Time elapsed between MRSA/VRE positive culture result and contact precautions order 
for 887 patients isolated following a culture result by quarter 
 
We attempted to estimate the true rate of contact precaution implementation, 
since, as previously noted, some patients without isolation orders nevertheless have 
appropriate precautions implemented on the hospital ward. An automated program 
identified all inpatient positive MRSA and VRE cultures from May-June 2007. Again, 
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with IRB approval, the project leader (R.C.) manually cross-checked those patients for 
whom an automated program indicated no contact precautions order had been entered in 
the CPOE logs against the manually generated ICP contact precautions records that had 
been stored in MicroDash. Of the 127 inpatients during the time period who had at least 
one positive MRSA or VRE culture (107 with MRSA and 20 with VRE), review of 
CPOE records indicated that contact precaution orders were present for 65 (51.2%). For 
the 62 culture-positive patients without a CPOE contact precautions order, review of ICP 
records indicated that 42 (67.7% of the 62, and 16.6% overall) of the patients had indeed 
been placed on contact precautions at some point during their hospitalization, yielding a 
total of 107 of the original 127 patients (84.3%) who were correctly placed on contact 
precautions. 
We assumed that the rate determined by our audit of 67.7% of all culture-positive 
patients who did not have an identified contact precautions order but were actually on 
contact precautions was a valid approximation for use on retrospective data. Thus, out of 
the initial 2,268 patients in our previously described retrospective study, 1,019 had 
contact precautions orders identified from the CPOE system logs, and we then estimated 
that 846 had contact precautions orders that could not be detected, yielding an overall 
contact precautions implementation rate of 82.2%. Figure 11 shows the CPOE-ordered 
and estimated overall contact precautions implementation rates by quarter for the study 
period. Because the ICPs do not collect information on the time contact precautions were 
initiated, we cannot evaluate the time lapse between the positive culture to the contact 
precautions order in the group for which we could not automatically detect the order. 
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Figure 11: Contact precautions implementation rates for inpatients with MRSA or VRE positive 
culture 
Summary and Conclusions: Retrospective Analysis of Contact Precautions 
Principal Findings 
Though VUH clinicians generally follow contact precautions policy correctly, the 
retrospective study suggests that approximately 1 out of every 5 patients with a new 
MRSA or VRE positive culture does not receive the proper hospital-policy-recommended 
contact precautions. Even when staff correctly initiate contact precautions, the orders are 
not always implemented immediately following a positive culture. Failing to follow 
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contact precautions for any length of time might potentially lead to an outbreak of 
infections.  
Because contact precautions are an infection control measure rather than a method 
of treating an individual patient’s symptoms, a clinician may not remember to order them 
without some external reminder. The ICPs often provide reminders, but using highly 
skilled and already busy ICPs to perform clerical duties such as telephoning clinicians is 
a tedious use of their time. Given the importance of contact precautions and the current 
lack of a better way to remind clinicians, however, the ICPs currently do not have any 
other options. 
MicroDash has anecdotally helped the ICPs in the identification of patients with 
MRSA or VRE positive cultures. Feedback from the ICPs has suggested that the real-
time dashboard provides them with earlier notice of antibiotic-resistant infections than 
relying on the telephone calls from the microbiology lab. On several occasions, 
microbiology lab staff called several hours after the new report appeared on MicroDash. 
In addition, during the study, clinical staff notified the ICPs that one patient on contact 
precautions did not have an antibiotic-resistant infection. MicroDash showed this patient 
as having MRSA. After closer examination, the ICPs determined that the original Triple-
G® microbiology report contained a methicillin-sensitive S. aureus isolate that was 
incorrectly labeled as methicillin-resistant. Searching the MicroParse database yielded 7 
additional cases of methicillin-sensitive S. aureus labeled in Triple-G® as MRSA, along 
with 8 cases of methicillin-resistant coagulase positive Staphylococcus (i.e., S. aureus) 
that had not been labeled as MRSA in Triple-G®. 
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Study Limitations 
The high rate (67.7%) of missed contact precautions implementation for those 
culture-positive patients lacking CPOE orders for precautions suggests that the methods 
MicroDash currently uses to retrieve orders may be systematically missing orders. 
Clinicians may also frequently forget to use the CPOE system to place orders, instead 
issuing them informally as verbal requests. However, given the CPOE system’s central 
role in the VUH medical culture, it seems surprising that nearly half of the contact 
precautions orders initiated at VUH are not being entered into the CPOE system. Further 
study into how physicians order contact precautions could provide valuable insight that 
might help MicroDash better judge contact precautions status for a patient. 
When measuring the time between the positive culture result and the initiation of 
contact precautions, we used the time of the contact precautions order. If contact 
precautions generally start before clinicians enter the contact precautions orders into the 
CPOE system, however, the study may have systematically overestimated the time lapse. 
Nonetheless, driving down the time between the positive culture result and the CPOE 
order still represents a helpful goal. If clinicians always enter their contact precautions 
orders in the CPOE system and on time, the ICPs would no longer need to conduct 
walking rounds to accurately assess a patient’s contact precautions status. 
Finally, while MicroDash can help make information gathering easier for the 
ICPs, the task of reminding clinicians to order contact precautions remains. We plan to 
create a CPOE-based alert to automatically remind clinicians to order contact precautions 
for patients who require them. 
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Significance of Results 
The retrospective study of contact precautions demonstrated that compliance with 
VUH contact precautions policy can be improved. Future work in this area should target 
3 areas: (1) increasing contact precautions ordering rates for patients with MRSA or VRE 
positive cultures, (2) increasing the number contact precautions orders entered through 
CPOE, and (3) decreasing the time between an MRSA or VRE positive culture and 
initiation of contact precautions. 
MicroDash provides the ICPs with a real-time tool to monitor antibiotic resistance 
in the hospital. By building in more flexibility into MicroDash, it could replace some of 
their currently non-automated workflow (e.g., the daily contact precautions status 
spreadsheet). 
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CHAPTER IV 
DEVELOPMENT OF A COMPUTERIZED ANTIBIOGRAM 
Introduction: Development of a Computerized Antibiogram for VUH 
An antibiogram is a table or chart that summarizes all patient culture sensitivity 
results for a given time period – by organism isolated -- for a hospital or for selected 
clinical units within a hospital or clinic. Antibiograms provide useful tools for 
determining which antibiotics to select when treating an infection especially before 
sensitivities are reported for the organism(s) causing a specific patient’s infection. 
Because antibiotic resistance patterns can change drastically over time, a previously 
effective antibiotic for treating Gram-negative-rod related infections years or even 
months ago may be almost useless at the present time.  
We developed a computerized antibiogram construction tool to give VUH clinical 
users the most up-to-date information about antibiotic resistance possible using 
electronically available resources. We hypothesized that the tool will help improve 
patient care, but have only begun to evaluate its effectiveness in a number of settings. 
Prior to this study, VUH microbiology lab staff had to manually collect all antibiotic 
resistance data from a given period of time in order to create antibiograms. With the large 
number of cultures conducted at VUH, this presented a very difficult and time-consuming 
task. Using cumulative microbiology data stored by MicroParse, we created an automated 
antibiogram tool, called MicroGram. 
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Methods: Development of a Computerized Antibiogram for VUH 
Creating and Evaluating an Antibiogram 
MicroGram constructs antibiograms following standard guidelines for doing so 
that are published by the Clinical and Laboratory Standards Institute (CLSI) [94]. First, 
MicroGram selects an appropriate window of time (3-6 months prior to the current date). 
It then retrieves all antibiotic sensitivity data from MicroParse for that time frame. The 
CLSI standard recommends using only the first isolated organism (of each type) per 
patient to generate the antibiogram to avoid counting a single isolated bacterium several 
times when a patient has several cultures positive for that organism within a short 
timeframe. Thus, MicroGram discards all sensitivities for which an earlier matching 
isolate (organism, not sensitivity pattern) exists from the same patient.  
Whenever the time period of interest includes at least 10 unique case-isolates for a 
given organism/antibiotic pair, MicroGram calculates the percentages of isolates for that 
organism that were sensitive, intermediate, and resistant to each tested antibiotic. If 
MicroGram finds the time period contains fewer than 10 isolates for an 
organism/antibiotic pair, it queries the MicroParse database for all historical sensitivity 
data for that pair, not limited to the index time period. If MicroGram finds 10 isolates in 
the complete historical data set, it will perform the sensitivity rate calculations for the 
organism/antibiotic pair; otherwise, MicroGram skips the pair in calculating the 
antibiograms. 
Once MicroGram has calculated all sensitivity percentages, it caches a table 
containing the organism names, antibiotic names, and sensitivity percentages on the 
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StarPanel servers and generates a graphical representation for the sensitivity patterns of 
each organism/antibiotic pair. To view the data, users can access either of two different 
MicroGram web interfaces. The first interface provides a standard grid (simple tabular) 
antibiogram, a form often used when manually constructing antibiograms. This view 
allows clinicians to compare the efficacy of an antibiotic on different organisms. The 
second interface provides a graphical view of the resistance patterns for one organism at a 
time. Both views allow the user to examine antibiograms for particular units or for certain 
culture types. Figure 12 and Figure 13 in Appendix A show the two interfaces. 
To assess the validity of the antibiograms MicroParse generates, we selected two 
organisms and manually constructed an antibiogram for them using “raw” Triple-G® 
output. We chose Acinetobacter baumannii, since different isolates often have different 
resistance patterns, and Morganella morganii, a less commonly observed organism that 
would likely require more than 6 months of data to find 10 isolates. 
To assess the clinical usefulness of each MicroGram interface, a formative 
evaluation enlisted several clinicians to review both versions of the antibiogram and to 
then complete a survey. The survey instrument is shown in Figure 14 in Appendix A.  
Results: Development of a Computerized Antibiogram 
Antibiogram Validation 
 
Project member R.C. reviewed 171 VUH culture and sensitivity reports for 
Acinetobacter baumannii from January to July, 2007 and found 71 distinct medical 
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record numbers in that time period. Project member R.C. reviewed 11 VUH culture and 
sensitivity reports for Morganella morganii January to July, all from distinct medical 
record numbers. For several antibiotics (amoxicillin/clavulanic acid, 
ampicillin/sulbactam, ampicillin, cefazolin, imipenem, minocycline, and nitrofurantoin), 
retrieving 10 tested isolates required a search in a more than a year-long interval. The 
manually generated antibiograms matched those generated by MicroGram. Table 1 shows 
the corresponding MicroGram antibiogram for A. baumannii and Table 2 shows the 
MicroGram result for M. morganii. No antibiotics were consistently effective against A. 
baumannii, but amikacin and imipenem were always effective against M. morganii. 
Table 1: Antibiogram for Acinetobacter baumannii in VUH as of July 23, 2007 
Antibiotic % sensitive n Days 
Amikacin 34 71 180 
Amox/Clav Acid 0 13 182 
AMP/Sulbactam 31 64 180 
Ampicillin 0 13 182 
Cefazolin 0 13 182 
Cefepime 4 71 180 
Cefotaxime 1 71 180 
Gentamicin 24 71 180 
Imipenem 26 66 180 
Levofloxacin 20 71 180 
Minocycline 35 62 180 
Nitrofurantoin 0 13 182 
Pip/Tazo 18 71 180 
Sulfa Trimethoprim 23 71 180 
Tobramycin 30 69 180 
 
 46 
 
Table 2: Antibiogram for Morganella morganii in VUH as of July 23, 2007 
Antibiotic % sensitive n Days 
Amikacin 100 11 180 
Amox/Clav Acid 0 10 399 
AMP/Sulbactam 40 10 363 
Ampicillin 0 10 399 
Cefazolin 0 10 399 
Cefepime 64 11 180 
Cefotaxime 45 11 180 
Gentamicin 73 11 180 
Imipenem 100 10 363 
Levofloxacin 64 11 180 
Minocycline 20 10 363 
Nitrofurantoin 0 10 399 
Pip/Tazo 91 11 180 
Sulfa Trimethoprim 55 11 180 
Tobramycin 91 11 180 
 
Clinician Formative MicroGram Survey Results 
Nine volunteer clinicians (1 internist, 2 surgeons, 4 infectious disease specialists, 
1 microbiologist, and 1 pulmonologist) received by e-mail a link to the sample 
MicroGram antibiograms with a second link to the survey instrument. After the nine 
volunteers shared the link with a few colleagues, we received 10 survey responses. Table 
3 shows the responses to each of the survey questions. Feedback was largely positive, and 
all survey takers agreed that the data contained in the antibiogram appeared to be correct. 
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Table 3: Antibiogram survey results 
Question Mean response 
1. Overall, this antibiogram would be useful  
(1=Strongly agree, 5=Strongly disagree) 
1.1 (range:1-2) 
2. The antibiogram is clear and easy to read  
(1=Strongly agree, 5=Strongly disagree) 
1.4 (range:1-2) 
3. View preference: 4 prefer grid view 
2 prefer individual view  
4 no preference 
4. Antibiograms would provide data I need for patient 
care that is not currently readily available  
(1=Strongly agree, 5=Strongly disagree) 
1.4 (range: 1-4) 
5. Having an online antibiogram available will improve 
the care of my patients  
(1=Strongly agree, 5=Strongly disagree) 
1.1 (range: 1-2) 
6. If regularly available, I would use an antibiogram: 5 would use weekly 
5 would use daily 
 
Feedback on the free text sections of the survey suggested that clinicians would 
primarily use an antibiogram to keep abreast of antibiotic sensitivity patterns and to help 
in antibiotic selection, particularly when deciding on an early course of empiric therapy. 
The survey responses also contained several layout change suggestions (e.g., label Gram-
positive and Gram-negative tables in the grid view, include antibiotic trade names to 
reduce the possibility of errors) that will be incorporated into future versions of 
MicroGram. 
Summary and Conclusions: Development of a Computerized Antibiogram 
Principal Findings 
The positive survey results suggest that VUH clinicians recognize the potential 
for MicroGram to improve patient care once it is fully implemented. The results also 
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suggest that MicroGram can potentially provide an effective means of accessing 
antibiogram information. Based on the free text responses, some fine tuning, but no major 
changes, should be carried out for the two MicroGram (grid view and individual 
organism view) displays. 
Study Limitations 
Because we directly asked the clinicians to volunteer to participate in the informal 
formative evaluation of MicroGram, the survey results may be biased in favor of the 
importance of antibiograms. The clinicians who participated were primarily those who 
would stand to benefit most from having an antibiogram available (e.g., trauma surgeons 
and infection control physicians).  
The current implementation of MicroGram is near real-time but slow enough to 
be of concern if physicians want to rapidly review a number of sensitivity patterns for 
various clinical settings. For the initial version of MicroGram, queries used to extract the 
information from the MicroParse database originally took approximately 5-10 minutes 
for each specific antibiogram (e.g. all VUH cultures, VCH urine cultures, 10N BAL 
cultures). Performing each query sequentially upon end-user requests for data would 
entail a slow and frustrating end-user experience. Creation of additional indices in the 
MicroParse database reduced the query time to 30-90 seconds each, but this performance 
level remains unacceptable for actual clinical use. The current plan is to improve 
MicroGram’s response times by running all possible queries (possibly staggered in time) 
daily and caching the results. Then MicroGram could generate antibiograms from cached 
data much more efficiently. Alternative approaches include methods to cache portions of 
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the data while still retrieving new culture data when loading MicroGram, thus giving the 
user the most current antibiogram possible.  
Significance of Results 
MicroGram provides VUH clinicians with antibiograms that can help improve 
antibiotic selection and therefore patient safety. Since MicroGram can generate the 
antibiograms without requiring human assistance, there tedious work of constructing 
them at infrequent intervals is no longer an obstacle to clinical care. 
 
 50 
 
CHAPTER V 
SYNOPSIS AND CONCLUSIONS 
Summary 
This project provided VUH clinicians and staff with new computerized tools to 
improve patient care. The MicroParse tool allows its users to search the microbiology 
results database flexibly, facilitating a number of approaches to monitoring 
microbiological data. The MicroGram tool gives VUH clinicians important data that can 
assist in antibiotic selection and to monitor for new patterns of antibiotic resistance. The 
MicroDash tool provides VUH ICPs with a means of tracking inpatients with a history of 
antibiotic-resistant colonization or infection, and a rapid notification mechanism to 
identify new patients with these conditions. The retrospective analysis of compliance 
with VUH contact precautions policy demonstrated that there are opportunities to 
improve the ordering of contact precautions for eligible inpatients with MRSA or VRE 
isolates and to improve the timeliness of the contact precaution orders following a new 
positive MRSA or VRE culture result.  
Future Directions 
To take advantage of the opportunities to improve compliance with contact 
precautions policy, we plan to develop a CPOE-based alert that will remind clinicians to 
order contact precautions for patients who require them based on culture results. Because 
MicroParse can provide real-time microbiology results, the CPOE system, informed by 
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MicroParse, can generate these alerts during the first ordering session immediately 
following the positive culture result. Through this approach, we hope to not only improve 
the percentage of patients properly placed on contact precautions but also the timeliness 
of the orders. 
Since the current method of storing the microbiology data in the MicroParse 
database uses the coded phrases from the VUH Microbiology Thesaurus, any programs 
created that using the data will not be interoperable with other systems. To remove this 
limitation, we hope to abstract out the VUH Microbiology Thesaurus by either finding or 
creating a basic microbiology terminology that we can then use to “tag” phrases. These 
tags will allow MicroParse to merge phrases referring to the same concept and to 
combine phrases logically (e.g., combining information about quantity with information 
about the organism isolated). Furthermore, it will allow VUH to share programs with 
other institutions if both sites are using the same terminology. 
Finally, while MicroGram provides antibiogram data to VUH clinicians, it does 
not provide any active assistance in antibiotic selection. To provide this assistance, we 
would like to develop a computer-based antibiotic advisor. An antibiotic advisor similar 
to the kind developed at LDS Hospital in Salt Lake City [53, 55] could streamline the 
antibiotic selection process, from empiric therapy to final antibiotic selection once 
sensitivity information is available.  
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SUPPLEMENTARY FIGURES 
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Figure 12: Individual organism view in MicroGram 
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Figure 13: Grid view in MicroGram 
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Figure 14: Antibiogram development survey 
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